Long‐term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large‐scale population‐based analysis

Mazzone, Elio; Mistretta, Francesco A.; Knipper, Sophie; Palumbo, Carlotta; Tian, Zhe; Pecoraro, Angela; Preißer, Felix; Gallina, Andrea; Shariat, Shahrokh F.; Saad, Fred; Graefen, Markus; Montorsi, Francesco; Briganti, Alberto; Karakiewicz, Pierre I.

doi:10.1111/bju.14841

Cited by 18 publications

(6 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The risk of SPM could be increased by interactions between common etiological factors, particularly an unhealthy lifestyle (e.g., long-term tobacco use, excessive intake of alcohol), genetic susceptibility, environmental exposure, and patient factors (7,9). In addition, research has shown that SPM can develop as a result of the late effects of certain treatments [e.g., radiotherapy, chemotherapy (10,11)].…”

Section: Introductionmentioning

confidence: 99%

Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study

et al. 2021

View full text Add to dashboard Cite

PurposeSecond primary malignancy (SPM) is challenging for treatment and long-term survival. We sought to investigate the standardized incidence rate (SIR), risk factors, and survival outcomes for SPM after renal cell carcinoma (RCC) treatment.MethodA nested case-control study was designed, we identified all T1-4N0-1M0 RCC patients diagnosed between 2004 and 2015 in the Surveillance, Epidemiology, and End Results database and followed them for SPM diagnosis for up to 13 years. Patients with SPM diagnosis ≥6 months after treatment of primary T1-4N0-1M0 RCC were identified as the case cohort and SPM-free patients were the control cohort. SIRs and the excess risk were calculated. A competing risks and Cox model were used to evaluate the risk factors of SPM and overall survival (OS).ResultsA cohort of 6,204 RCC patients with SPM were matched with a control group of 31,020 RCC patients without SPM. The median time-to-SPM interval was 54.5 months in RCC patients with SPM diagnosis. Besides, an SPM of T3/4 or/and M1 stage diagnosis was positively associated with a longer time-to-SPM interval. SIR of SPM increased by follow-up time and decreased with age at diagnosis (Pfor all <0.001). SPM in the kidney had the highest SIR (54.6, P <0.001) among all SPMs. Prostate cancer (29.8%) in males and breast cancer (23.5%) in females were the most common SPM. Older age, black ethnicity, male sex, higher family income, papillary RCC, and lower TNM stage were significant risk factors for SPM diagnosis. The proportion of deaths from SPM exceeds that of deaths from RCC 3 years after the first RCC treatment. Patients with SPM and early time-to-SPM interval shortens the OS compared with SPM-free patients. The 5-year OS was 85.9% and 58.9% from the first RCC and the SPM diagnosis, respectively. Besides, patients with low-grade/early-stage SPM could benefit from aggressive surgical treatment for solid tumors.ConclusionsCollectively, our study described the epidemiological characteristics of SPM among RCC survivors and identified the independent predictors of the SPM diagnosis and its survival outcomes. This study highlights the importance of patient education and follow-up after the surgery for RCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Furthermore, we found that the main hematological cancers, Kaposi sarcomas and gastrointestinal tract (GIT) tumors were cancers with the risk of occurring before (BL/L as an SPC) or after (any cancer other than BL/L as an SPC) BL/L. Other population-based studies also using the SEER Program reported the occurrence of further malignancies after a previous cancer including prostate [ 28 ], breast [ 29 ] and chronic myeloid leukemia [ 30 ].…”

Section: Discussionmentioning

confidence: 95%

Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma/Leukemia

et al. 2021

View full text Add to dashboard Cite

Burkitt lymphoma/leukemia (BL/L) is an aggressive oncohematological disease. This study evaluated the population-based prognosis and survival on BL/L as well as if BL/L behaved as a risk factor for the development of second primary cancers (SPCs) and if other first tumors behaved as risk factors for the occurrence of BL/L as an SPC. A retrospective cohort using the Surveillance, Epidemiology and End Results (SEER) Program (2008–2016) was performed. Kaplan–Meier, time-dependent covariate Cox regression and Poisson regression models were conducted. Overall, 3094 patients were included (median, 45 years; IQR, 22–62). The estimated overall survival was 65.4 months (95% CI, 63.6–67.3). Significantly more deaths occurred for older patients, black race, disease at an advanced stage, patients without chemotherapy/surgery and patients who underwent radiotherapy. Hodgkin lymphomas (nodal) (RR, 7.6 (3.9–15.0; p < 0.001)), Kaposi sarcomas (34.0 (16.8–68.9; p < 0.001)), liver tumors (3.4 (1.2–9.3; p = 0.020)) and trachea, mediastinum and other respiratory cancers (15.8 (2.2–113.9; p = 0.006)) behaved as risk factors for the occurrence of BL/L as an SPC. BL/L was a risk factor for the occurrence of SPCs as acute myeloid leukemias (4.6 (2.1–10.4; p < 0.001)), Hodgkin lymphomas (extranodal) (74.3 (10.0–549.8; p < 0.001)) and Kaposi sarcomas (35.1 (12.1–101.4; p < 0.001)). These results may assist the development of diagnostic and clinical recommendations for BL/L.

show abstract

“…Curative treatment of prostate cancer mainly consists of prostatectomy with or without RT and/or ADT according to the estimated risk of recurrence [ 9 ]. Patients with prostate cancer who receive RT are at higher risk of secondary malignancies, such as bladder and rectal cancers [ 10 – 12 ]. In our case, rectal cancer was found 1.5 years after diagnosis of prostate cancer, which was treated with RT, therefore, it is likely that the rectal cancer was caused by RT for prostate cancer.…”

Section: Discussionmentioning

confidence: 99%

Diagnostic pitfalls: a case of prostate cancer and rectal cancer accompanied by prostate cancer invasion of the rectum

Long

Peng

et al. 2022

Diagn Pathol

View full text Add to dashboard Cite

Introduction Case of double primary cancer of the prostate and rectum is rare, prostate cancer involving the postoperative intestinal anastomotic mucosal tissue is even rarer. Case presentation We report a case of rectal cancer discovered 1 year after a diagnosis of prostate cancer and a tumour in the postoperative anastomotic intestinal mucosal tissue involving prostatic adenocarcinoma at 1 year after the diagnosis of rectal cancer. Due to the poor differentiation of both prostate and rectal cancers, there are some pitfalls in the diagnosis of intestinal mucosal lesions at an anastomosis. The lack of an accurate diagnosis of a tumour in anastomosis intestinal mucosal tissue will affect treatment and patient survival. Conclusions The pathologists should have a detailed understanding of the patient's medical history and carefully observe the histopathological morphology and, if necessary, immunohistochemistry or other techniques should be used to assist in the pathological diagnosis and avoid both misdiagnosis and missed diagnosis.

show abstract

Long‐term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large‐scale population‐based analysis

Abstract: ConclusionsBrachytherapy predominantly increases the risk of secondary BCa and, to a lesser extent, that of RCa. Follow-up of such patients is therefore required. It is encouraging that both secondary BCa, and RCa rates, in particular, have recently decreased, RCa.

Cited by 18 publications

References 18 publications

Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study

Standardized Incidence Rate, Risk and Survival Outcomes of Second Primary Malignancy Among Renal Cell Carcinoma Survivors: A Nested Case-Control Study

Prognostic Factors, Survival Analyses and the Risk of Second Primary Cancer: A Population-Based Study on Burkitt Lymphoma/Leukemia

Diagnostic pitfalls: a case of prostate cancer and rectal cancer accompanied by prostate cancer invasion of the rectum

Contact Info

Product

Resources

About